Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

The four main types of leukemia, and why the difference matters

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Saying someone has leukemia is a bit like saying someone has a lung problem. The word covers conditions that differ in who gets them, how fast they move, how they are treated and how they end.

Two questions sort almost all of them.

Illustration of a stained blood smear showing round purple leukemia blast cells with large nuclei among pale pink red blood cells and small platelets.
A stained blood smear, the view that first revealed leukemia in the 1840s and still sorts it today. The deep purple cells are blasts, almost filled by their own nucleus. Their size, shape and staining are the first clue to which type of leukemia it is, before the genetic tests confirm it.Illustration created for OwieClear. A drawing, not a photograph of a real sample.

Related pages: Leukemia (blood cancer)

The bottom line

What we know
  • Acute means immature blasts building up fast; chronic means more mature cells accumulating slowly.
  • Lymphocytic means the lymphoid line; myeloid means the myeloid line.
  • ALL is the most common childhood cancer and is usually curable in children.
  • Some chronic leukemias are watched rather than treated at diagnosis.
What is still open
  • Why childhood ALL responds so much better to the same drugs than adult ALL does.
  • When, and whether, treatment can safely be stopped in chronic myeloid leukemia.

The story, step by step

  1. 1. The two questions ()
  2. 2. ALL ()
  3. 3. AML ()
  4. 4. CLL ()
  5. 5. CML ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

Fast or slow, and which line

Review of many studies

What happens

The four classic names are just the four combinations.

What the research shows

  • Acute: the cells are stuck as immature blasts, numbers rise over days to weeks, and untreated acute leukemia is life-threatening quickly.
  • Chronic: the cells mature further and function partly, numbers build over months to years, and some people have no symptoms at diagnosis.
  • Lymphocytic or lymphoblastic: from the lymphoid line, the B- and T-cells.
  • Myeloid or myelogenous: from the myeloid line, which makes red cells, platelets and neutrophils.

Why it matters

Acute versus chronic is the difference between an emergency and a clinic appointment, which is why it is the first thing a haematologist establishes.

What's still uncertain

Read more

Next: ALL

Part 2 of 5

Acute lymphoblastic leukemia

Review of many studies

What happens

The most common cancer in children, and one of modern medicine's clearest successes.

What the research shows

  • It peaks between ages two and five, though it also occurs in adults, where it is harder to treat.
  • Common drivers include translocations such as ETV6-RUNX1 and, in some cases, BCR-ABL1, the same fusion seen in CML.
  • Presentation is usually fast: fatigue, bruising, fevers, bone or joint pain, and swollen lymph nodes over a few weeks.
  • Treatment is long, typically two to three years in phases, and includes medicine given into the spinal fluid because the central nervous system is a sanctuary site.
  • Survival in children has risen from almost zero in the 1950s to around 90 percent today.

Why it matters

Bone or joint pain in a child, especially with bruising, fatigue or fever, is one of the symptoms most often attributed to growing pains before a blood count is done.

What's still uncertain

  • Adult ALL outcomes remain considerably worse than children's, and why is not fully explained by biology alone.

Read more

Next: AML

Part 3 of 5

Acute myeloid leukemia

Review of many studies

What happens

The most common acute leukemia in adults, and the most varied genetically.

What the research shows

  • Risk rises steeply with age, with median diagnosis in the late sixties.
  • Common mutations include FLT3, NPM1, IDH1, IDH2 and DNMT3A, and the combination present decides both treatment and outlook.
  • Presentation is marrow failure: severe fatigue, bleeding or bruising, fever and infection, often over weeks.
  • One subtype, acute promyelocytic leukemia, is a true emergency because of a severe clotting and bleeding disorder, and is also among the most curable, treated with ATRA and arsenic trioxide rather than standard chemotherapy.
  • Treatment ranges from intensive chemotherapy to gentler combinations such as venetoclax with azacitidine for people who cannot tolerate intensive therapy.

Why it matters

APL is the reason a suspected acute leukemia with abnormal clotting is handled within hours rather than days. Recognizing it changes the drug entirely.

What's still uncertain

  • Older adults with AML still have poor outcomes overall, despite a decade of new drug approvals.

Read more

Next: CLL

Part 4 of 5

Chronic lymphocytic leukemia

Review of many studies

What happens

The most common leukemia in adults in Western countries, and the one most often found by accident.

What the research shows

  • It is usually discovered on a routine blood count showing a high lymphocyte count in someone who feels well.
  • Markers that matter include deletions of chromosome regions 13q, 11q and 17p, TP53 status, and whether the IGHV gene is mutated.
  • Many people need no treatment at diagnosis. Watchful waiting, with regular counts, is a legitimate and evidence-based plan, not neglect.
  • When treatment is needed, BTK inhibitors and the BCL-2 inhibitor venetoclax have largely replaced chemotherapy.
  • Common problems include recurrent infections, autoimmune destruction of red cells or platelets, and swollen lymph nodes.

Why it matters

Being told you have a leukemia and also that nothing will be done about it today is one of the hardest things to accept, and for CLL it is often the right plan.

What's still uncertain

  • Treating early CLL before symptoms appear has been tested and has not improved survival, which is why waiting is standard.

Read more

Next: CML

Part 5 of 5

Chronic myeloid leukemia

Review of many studies

What happens

The disease that proved targeted cancer therapy could work.

What the research shows

  • Nearly every case is driven by the Philadelphia chromosome and the BCR-ABL1 fusion it creates.
  • It usually presents in a chronic phase, sometimes with no symptoms, sometimes with fatigue, night sweats, weight loss or an enlarged spleen.
  • Untreated, it eventually transforms into an acute, aggressive phase called blast crisis.
  • Imatinib, approved in 2001, and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term, with life expectancy approaching normal.
  • Some people with a deep, sustained response can stop treatment under close monitoring, known as treatment-free remission, though about half relapse and restart.

Why it matters

CML is the proof of concept for everything in modern precision oncology, and the reason identifying the exact driver mutation became routine.

What's still uncertain

  • Who can safely stop treatment, and for how long, is still being defined by ongoing trials.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.